Apr 19, 2010
SuppreMol Receives U.S. Orphan Drug Designation for SM101

Apr 12, 2010
SuppreMol initiates Phase Ib/IIa clinical trial with its lead candidate SM101

Feb 08, 2010
SuppreMol appoints Dr. Robert Phelps as Head of Business Development & Licensing

September 15-17, 2010
BioPharma America 2010, Boston, MA, USA

Corporate Fact Sheet (en)
Corporate Fact Sheet (de)
Press Resources

Prof. Peter Buckel im Video-Interview

SuppreMol's treatment strategy is based on unique expertise in the field of certain receptors of the immune system, the so-called Fcγ receptors (FcRs) which play a central role in the human immune system during the fight of infections, but also in autoimmune diseases. SuppreMol aims to unlock the therapeutic potential of these receptors in autoimmune diseases with a high, but unmet medical need.

SuppreMol is using Fcγ receptors either in a recombinant soluble version (sFcR) or as targets for an anti-FcR antibody. The sFcR down-regulates inflammation, cellular immune response, and B-cell activation and is initially developed in the orphan disease Idiopathic Thrombocytopenic Purpura (ITP), thereby bridging to indications with bigger markets like Systemic Lupus Erythematosus and Rheumatoid Arthritis.

The anti-FcR antibody recruits FcγRIIb for the treatment of autoimmune diseases that are not adequately addressed by SM101. Finally, SuppreMol evaluates in-licensing opportunities to complement its current projects in order to further increase the Company’s development pipeline and intellectual property.

The Company was founded in 2002 as a spin-off from the laboratory of Prof. Dr. Robert Huber, Nobel Prize winner in Chemistry in 1988 and Head of the renowned X-ray Crystallography Department at the Max Planck Institute for Biochemistry in Martinsried/Germany. In addition to Prof. Robert Huber, Dr. Uwe Jacob and Dr. Peter Sondermann, now Chief Scientific Officer (CSO) of the Company belonged to the founder team.

Download Corporate Fact Sheet